Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are a novel class of injectable incretin mimetics that provide glycaemic and extra-glycaemic benefits for the treatment of patients with type 2 diabetes [6]. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.